Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 507

Three companies with balance sheet strength and opportunities

Emma Fisher is Portfolio Manager of the Airlie Australian Share Fund. She discusses the Airlie portfolio and highlights companies she currently favours with Jennifer Herbert, Head of Listed Funds at Magellan.

JH: CSL is one of the largest positions in the portfolio, and you were recently in Europe at a CSL site visit. What key takeaways from that visit?

EF: Over the last five years, CSL has spent nearly US$6 billion on capital expenditures (capex). It was great to see in person what they've built. CSL has been a phenomenal success story but over the last few years, the share price has been range bound $250 and $300 due to a decline in returns. In 2018, they made a 31% return on invested capital, and last year, it had fallen to about 20%.

Three things have weighed on returns. First, plasma collection costs rose in the US where they pay donors to donate plasma at their facilities. Pre-pandemic, the cost was US$60 per visit, but the cost went to over $100 during the pandemic as people stayed home. A second factor is all the capex, including a massive increase in their fractionation capacity. And third was the 2022 acquisition of Swiss pharmaceuticals maker, Vifor.

One of the reasons we've been adding to our position is that these three factors that weighed on returns are now going the other way. Donor fees are falling fast, and the capex has delivered highly automated, state-of-the-art manufacturing capacity. We think the returns will improve as those assets come online. And finally, having visited the Vifor assets in Switzerland as part of this tour, I think got my head around what they see in this business. CSL has been successful in broadening the applications for its products. Vifor’s primary product is intravenous iron, which probably should be used a lot more. To give an example, if you need surgery but you’re anemic, you should have an iron infusion with a Vifor product. You will typically have better outcomes in the surgery and be much less likely to need a blood transfusion. So, it's a similar CSL DNA of building out indications for the iron products that they've bought. You can see long term how that acquisition could be a success.

JH: What other takeaways are there for the portfolio from your European trip?

EF: The vibe in Europe in general, and in particular in London, would be summarised as surprisingly resilient. In Australia, the headlines suggest a dire economic situation over the last 12 months, but I think they took a lot of pain last year and there's almost a sense of relief that they've come through the winter a little bit better. The Government stepped in and capped energy costs for households.

Of the relevant meetings for stocks we own in the portfolio, one of the standouts was QBE. It's been a sort of perennial underperformer but outside of North America, the international business has always been good. The key for that business is the underwriting of risk. It was pleasing to hear in our meetings that QBE has a fantastic reputation in the London community and is able to attract really highly talented underwriters. The insurance cycle has seen significant rate rises for a few years and we expect that to continue. And obviously, insurers also have the kicker of higher interest rates working through their investment book.

The other one in the portfolio is Tabcorp, for us a classic turnaround story. In their wagering business, we met a competitor of Tabcorp that was forthright that they'd seen an improvement in the last 18 months in Tabcorp's competitive offering. That was really pivotal for us as they’ve also launched a new wagering app.

JH: What's your view on the Australian banks? Do you think there's a risk of contagion from the problems at smaller US banks?

EF: It's never say never with the banks because they are highly geared vehicles, but on the face of it, I don’t see much risk of contagion for the Aussie banks. That said, when I look at the cycle, we must be aware that we are late in a tightening cycle globally, and this is the point of the cycle where things start to go bump in the night. Our reading of the SVB and Credit Suisse situations is that they look idiosyncratic. However, the Aussie Banks show the importance of having a low-cost, sticky deposit franchise, and the Australian banks have had access to incredibly cheap funding over the last few years. Now that's come to an end, the banks need to replace those funding sources with more expensive sources, and the recent banking crisis in the US and Europe has increased wholesale funding rates. The real standout performer is the Commonwealth Bank, with far and away the largest deposit franchise in Australia.

With respect to the portfolio, we remain significantly underweight the big four banks and I'm very comfortable with that position. We appear to be staring down at an economic downturn and while a bad debt cycle is not our base case for the banks, they are incredibly levered vehicles. It’s not worth being a hero with some of those downside risks.

JH: And commodity prices have been resilient considering the economic doom and gloom, and that's probably partially due to the China reopening. Where do you see the opportunities in this space?

EF: Yes. At Airlie, we are bottom-up stock pickers, so, when we look at commodities, we're focusing on understanding the supply dynamics as well as where these assets sit on the cost curve and the industry structure. Through that lens, a lot of the noise is always generated by demand side factors, and China reopening is an example of that. But over the long term, I think that the returns that a company generates and the returns as an investor in resources companies are much more dictated by the supply side dynamics. So, that's where we spend a lot of our time focusing, especially understanding where an asset sits on the cost curve.

Through that lens, we have owned Mineral Resources for a long time. It's been our best performer. The returns from here will be driven by the lithium price and the penetration story of electric vehicles. The supply-demand perspective is giving conflicting signals. The demand side signals look quite weak. Price are falling, Chinese EV sales are disappointing and the subsidies might be hit by a recession. But the supply side signals look quite positive long-term for pricing as it’s costing other producers more to bring their assets online. And Mineral Resources will be a great beneficiary of that. I've got no idea where pricing is going in the short term, but over the long term, I see a positive skew from that supply-demand setup.

JH: In light of everything we've talked about, how is the portfolio positioned for the current market?

EF: There’s always doom and gloom and a lot of noise and a lot of headlines. I think if we are going into a recession, it's got to be the most well-heralded, most well-anticipated recession of all time. So, for us, we like this kind of environment because we think in that volatility you can find opportunity. One thing we're always focused on at Airlie, but particularly at the moment, is the strength of balance sheets. The first step in our process is focusing on financial strength. Right now in particular, we want to own businesses that are not only protected from a balance sheet perspective in a downturn, but also have that opportunity on their side, particularly if they're going into a downturn with net cash. So, that's the lens that we're applying.

But we are still finding opportunities out there and businesses like CSL, Mineral Resources and QBE show from a bottom-up perspective the potential we are excited about.

 

Emma Fisher is Portfolio Manager on the Airlie Australian Share Fund. Airlie is part of the Magellan Asset Management Group, a sponsor of Firstlinks. This article is for general information purposes only, not investment advice.

For more articles and papers from Magellan, please click here.

 

RELATED ARTICLES

Emma Fisher on picking companies not trends or themes

banner

Most viewed in recent weeks

16 ASX stocks to buy and hold forever, updated

This time last year, I highlighted 16 ASX stocks that investors could own indefinitely. One year on, I look at whether there should be any changes to the list of stocks as well as which companies are worth buying now. 

UniSuper’s boss flags a potential correction ahead

The CIO of Australia’s fourth largest super fund by assets, John Pearce, suggests the odds favour a flat year for markets, with the possibility of a correction of 10% or more. However, he’ll use any dip as a buying opportunity.

2025-26 super thresholds – key changes and implications

The ABS recently released figures which are used to determine key superannuation rates and thresholds that will apply from 1 July 2025. This outlines the rates and thresholds that are changing and those that aren’t.  

Is Gen X ready for retirement?

With the arrival of the new year, the first members of ‘Generation X’ turned 60, marking the start of the MTV generation’s collective journey towards retirement. Are Gen Xers and our retirement system ready for the transition?

Why the $5.4 trillion wealth transfer is a generational tragedy

The intergenerational wealth transfer, largely driven by a housing boom, exacerbates economic inequality, stifles productivity, and impedes social mobility. Solutions lie in addressing the housing problem, not taxing wealth.

What Warren Buffett isn’t saying speaks volumes

Warren Buffett's annual shareholder letter has been fixture for avid investors for decades. In his latest letter, Buffett is reticent on many key topics, but his actions rather than words are sending clear signals to investors.

Latest Updates

Investing

Designing a life, with money to spare

Are you living your life by default or by design? It strikes me that many people are doing the former and living according to others’ expectations of them, leading to poor choices including with their finances.

Investment strategies

A closer look at defensive assets for turbulent times

After the recent market slump, it's a good time to brush up on the defensive asset classes – what they are, why hold them, and how they can both deliver on your goals and increase the reliability of your desired outcomes.

Financial planning

Are lifetime income streams the answer or just the easy way out?

Lately, there's been a push by Government for lifetime income streams as a solution to retirement income challenges. We run the numbers on these products to see whether they deliver on what they promise.

Shares

Is it time to buy the Big Four banks?

The stellar run of the major ASX banks last year left many investors scratching their heads. After a recent share price pullback, has value emerged in these banks, or is it best to steer clear of them?

Investment strategies

The useful role that subordinated debt can play in your portfolio

If you’re struggling to replace the hybrid exposure in your portfolio, you’re not alone. Subordinated debt is an option, and here is a guide on what it is and how it can fit into your investment mix.

Shares

Europe is back and small caps there offer significant opportunities

Trump’s moves on tariffs, defence, and Ukraine, have awoken European Governments after a decade of lethargy. European small cap manager, Alantra Asset Management, says it could herald a new era for the continent.

Shares

Lessons from the rise and fall of founder-led companies

Founder-led companies often attract investors due to leaders' personal stakes and long-term vision. But founder presence alone does not guarantee success, and the challenge is to identify which ones will succeed in the long term.

Sponsors

Alliances

© 2025 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.